A recent phase I/II clinical study of the humanized anti-CCR4 antibody, mogamulizumab, showed promising results in heavily pretreated patients, supporting an important role of the CCR4-CCL17/CCL22 axis in the pathogenesis of CTCL [54]. Here, CCR4 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.